Table 5. Details of the first two clinical studies of motor rehabilitation in larger cohorts in degenerative cerebellar disease [6, 7].
Ilg et al. [6, 96] | Miyai et al. [7] | |
---|---|---|
Number of patients | 16 | 42 |
Type of disease | SCA6(2), SCA2(1), ADCA(1), IDCA(6), FRDA(3), SANDO(2), SN(1) | SCA6(20), ADCA(6), IDCA(16) |
Age±SD (range) | 61.4±11.2 (44–79) | 62.5±8.0 (40–82) |
Gender | 8 males, 8 females | 22 males, 20 females |
Duration of disease | 12.9±7.8 (3–25 years) | 9.8±6.2(7 months–0 years) |
Baseline SARA | 15.8±4.3 (11–24) | 11.3±3.8 (5–21.5) |
Control | Intra-individual controls for short-term effect | Crossover for short-term effect |
Intervention | 1 h×3 per week× 4 weeks | 2 h × 5 +1 h × 2 per week × 4 weeks |
Post-training | Home training protocols | No |
Outcome measures | SARA, gait speed, balance, BBS, GAS, movement analysis | SARA, FIM, gait speed, cadence, FAC, falls |
Assessment point | 4 weeks pre, baseline, post 0, 8 weeks | Baseline, post 0, 4, 12, 24 weeks |
Main results | SARA and gait improved 8 weeks post-rehabilitation only in patients with cerebellar ataxia not afferent ataxia | SARA and gait improved 12 weeks but not 24 weeks |
SCA spinocerebellar ataxia, FRDA Friedreich's ataxia, IDCA idiopathic cerebellar ataxia, ADCA autosomal dominant cerebellar ataxia, SANDO sensory ataxic neuropathy with dysarthria and ophthalmoparesis caused by mutations in the polymerase gamma gene, SN sensory neuropathy, SARA Scale for the Assessment and Rating of Ataxia, BBS Berg Balance score [159], GAS Goal Attainment Scaling [160], FIM Functional Independence Measure [97], FAC Functional Ambulation Categories